» Authors » Aaron D Levine

Aaron D Levine

Explore the profile of Aaron D Levine including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 298
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Brinsfield T, Pinson N, Levine A
Stem Cells Transl Med . 2024 Jul; 13(9):851-858. PMID: 39045646
Unproven cell-based interventions (CBIs) emerged early in the 2000s as a particularly problematic form of unproven therapy and remain a vexing policy problem to this day. These unproven interventions can...
2.
Ikonomou L, Cuende N, Forte M, Grilley B, Levine A, Munsie M, et al.
Cytotherapy . 2023 Jul; 25(9):920-929. PMID: 37517865
The field of regenerative medicine, including cellular immunotherapies, is on a remarkable growth trajectory. Dozens of cell-, tissue- and gene-based products have received marketing authorization worldwide while hundreds-to-thousands are either...
3.
Zettler P, Ikonomou L, Levine A, Turner L, Grilley B, Roxland B
Cytotherapy . 2023 Apr; 25(7):712-717. PMID: 37097267
Patient interest in non-trial access pathways to investigational cell-and gene-based interventions, such as expanded access in the USA, is increasing, while the regulatory and business environments for non-trial access in...
4.
Hunckler M, Levine A
Front Bioeng Biotechnol . 2022 Oct; 10:949280. PMID: 36204464
Biomaterials--from implanted iron teeth in the second century to intraocular lenses, artificial joints, and stents today--have long been used clinically. Today, biomaterials researchers and biomedical engineers are pushing beyond these...
5.
Levine B, Munsie M, Levine A, Ikonomou L
Cytotherapy . 2022 Feb; 24(10):977-978. PMID: 35193823
No abstract available.
6.
Ho L, Robbins H, Levine A
Nat Biotechnol . 2022 Feb; 40(2):275-278. PMID: 35169309
No abstract available.
7.
Turner L, Munsie M, Levine A, Ikonomou L
Stem Cell Reports . 2021 Oct; 16(11):2567-2576. PMID: 34653406
The significant morbidity and mortality of coronavirus disease 19 (COVID-19) prompted a global race to develop new therapies. These include interventions using cell- or cell-derived products, several of which are...
8.
Kim Y, Levine A, Nehl E, Walsh J
Scientometrics . 2021 Mar; 125(3):2349-2382. PMID: 33746311
Science funders are increasingly requiring evidence of the broader impacts of even basic research. Initiatives such as NIH's CTSA program are designed to shift the research focus toward more translational...
9.
Ho L, Oso S, Levine A
Lancet Oncol . 2019 Sep; 20(8):1062-1064. PMID: 31486373
No abstract available.
10.
Wang K, Liu Y, Li J, Wang B, Bishop R, White C, et al.
Cytotherapy . 2019 Aug; 21(10):1081-1093. PMID: 31445816
Background Aims: Autologous cell therapy (AuCT) is an emerging therapeutic treatment that is undergoing transformation from laboratory- to industry-scale manufacturing with recent regulatory approvals. Various challenges facing the complex AuCT...